Sodium bicarbonate is the alkaline salt sold as baking soda and, in sterile 8.4% form, as an intravenous drug for metabolic acidosis.
What published studies and recent community write-ups report about amounts, timing and course length. 2 clinical and 5 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical2 rows | |||||
| FDA label: 8.4% injection for metabolic acidosisAdults and children with metabolic acidosis from renal disease, uncontrolled diabetes, shock, cardiac arrest, lactic acidosis or certain poisonings | 8.4% solution, 1 mEq/mL (84 mg/mL), 50 mEq per 50 mL vial | Dosed to arterial pH and blood gas monitoring | Intravenous only; hypertonic | Acute treatmentNot applicable | DailyMed, National Library of Medicine2026 |
| The label describes a hypertonic solution with a pH of 7.8 (7.0 to 8.5), adjusted with carbon dioxide, and warns that if it leaks out of a vein its alkalinity causes chemical cellulitis with tissue necrosis, ulceration or sloughing at the site. That warning is the most relevant line for anyone adding it to a subcutaneous injection: concentrated bicarbonate in tissue is caustic, which is why community use is measured in single insulin-syringe units diluted into millilitres of solution. | |||||
| FDA label: neutralising additive to reduce injection painPatients receiving lidocaine with epinephrine local anaesthetic | 8.4% sodium bicarbonate, 1 mEq/mL, in 1.7 mL and 2.7 mL single-use cartridges added to the anaesthetic | Once, immediately before the anaesthetic is injected | Admixed into the local anaesthetic solution | Single use; contains no bacteriostatNot applicable | DailyMed, National Library of Medicine2026 |
| This is the licensed version of the idea behind community use: the product is indicated to hasten the onset of analgesia and reduce injection pain by bringing an acidic drug solution closer to physiological pH. Its label also carries the two cautions that transfer directly to peptides. Raising the pH too far, above about 7.8, can make the drug precipitate out of solution, and a solution that has precipitated must not be injected; raising it well above physiological pH can itself irritate tissue. The label's reference list includes the Cochrane review on adjusting lidocaine pH. | |||||
| Community-reported5 rows | |||||
| Forum thread: buffering unbuffered NAD+ by pH strip | Reconstitute in 1.5-2 mL bacteriostatic water, test pH, add 1-5 insulin-syringe units of 8.4% bicarbonate at a time until pH 4 to 5 and never above 6, then add the remaining water; one member reported 2 mL water plus 0.7 mL of 8.6% bicarbonate reaching about pH 5 | Once, at reconstitution, with a venting needle for the carbon dioxide released | Subcutaneous use discussed by members | Members advise using the buffered vial within about 2 weeksNot applicable | Community resource2025 |
| The most concrete community description of the practice. Members are clear that no formula transfers between kits because the starting acidity differs, so the method is to add a little, test, and repeat, keeping a tally so the next vial in the same kit can be matched. The member who reached pH 5 reported no sting. The thread also records a failed attempt to have a chatbot compute the ratio, which is a fair summary of why titration rather than calculation is the community method. | |||||
| Forum thread: which diluent for which peptide | Bicarbonate for peptides that are too acidic, such as unbuffered NAD+; acetic acid for peptides that want a low pH; plain bacteriostatic water at about pH 7.2 for the rest | Chosen once, at reconstitution | Subcutaneous use discussed by members | Not stated | Community resource2024 |
| A short rule of thumb from a 2024 thread that places bicarbonate and acetic acid as opposites: one raises pH, the other lowers it, and the peptide's chemistry decides which, if either, is wanted. It is a community heuristic rather than a tested rule, and the same thread records members disagreeing about cagrilintide. | |||||
| Technical guide: bicarbonate as a mild base for acidic peptides | 0.1 M sodium bicarbonate solution, about pH 8.3, for peptides that need only a slight shift above neutral | As a solvent step, then diluted | Bench dissolution | Not stated | Community resource2026 |
| This guide positions bicarbonate as the gentler of the two bases used for acidic peptides, the other being ammonium hydroxide. It also states its weaknesses plainly: limited buffering capacity, and sensitivity to atmospheric carbon dioxide, so the pH of an unsealed solution drifts over time. For stored peptide solutions it recommends sealed containers with minimal headspace. A vial that is punctured repeatedly for weeks is the opposite of that. | |||||
| Manufacturer guideline: what the bench uses instead | A small amount of 0.1 M ammonium bicarbonate for acidic peptides, diluted with water and adjusted to about pH 7 | Once, on a test aliquot | Bench dissolution for laboratory use | Not stated | Community resource2026 |
| Supplier guidance for acidic peptides reaches for ammonium bicarbonate, not sodium bicarbonate, because the ammonium salt is volatile and can be removed by freeze-drying. Community users substitute the sodium salt because it is the one sold as a sterile injection. Both raise pH; the substitution is a matter of what is available in a sterile vial, not a chemical equivalence, and the same guideline warns that cysteine-containing peptides are unstable in basic solution. | |||||
| Community comment: the NAD+ target range | Buffer NAD+ to pH 5.5 to 6 with a carbonate or bicarbonate buffer, and no higher than 6 | Once, at reconstitution | Subcutaneous use discussed | Not stated | Community resource2026 |
| A commenter correcting a post that recommended acid for everything: NAD+ will not fully dissolve in an acidic solvent and wants an alkaline buffer, but becomes unstable above pH 6, so the window is narrow. The commenter also advises against phosphate buffer for this purpose. This is one experienced voice in a thread, recorded here because it states a specific target the forum thread above arrived at independently. | |||||
The peptide is dissolved in most of its bacteriostatic water first, and the pH is checked with a strip. Bicarbonate is only considered if the reading is low enough to sting or to leave the peptide undissolved.
The 8.4% injection is added one to five insulin-syringe units at a time, through a venting needle because acid plus bicarbonate releases carbon dioxide, with a pH check after each addition. The target quoted for NAD+ is 4 to 5, never above 6. The remaining water goes in last, less the bicarbonate volume already added.
In clinical practice the neutralising additive is drawn once into an acidic local anaesthetic immediately before injection, from a single-use cartridge with no preservative, and discarded. It is never titrated into a multi-dose vial, and its label warns that overshooting the pH precipitates the drug.
Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Sodium bicarbonate is the alkaline salt sold as baking soda and, in sterile 8.4% form, as an intravenous drug for metabolic acidosis. In peptide preparation it plays the opposite role to acetic acid: a few drops of the 8.4% injection are added to raise the pH of a solution that is too acidic, most often unbuffered NAD+, and to reduce the sting of an acidic injection. That second use has a licensed precedent, because an 8.4% sodium bicarbonate product is FDA-labelled specifically to be added to lidocaine so the injection hurts less, but no bicarbonate product is labelled for use with peptides, and the forum practice of titrating it by pH strip is a community method with known pitfalls.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Diluents and buffers a lyophilised vial is dissolved in.
The label describes a hypertonic solution with a pH of 7.8 (7.0 to 8.5), adjusted with carbon dioxide, and warns that if it leaks out of a vein its alkalinity causes chemical cellulitis with tissue necrosis, ulceration.
This is the licensed version of the idea behind community use: the product is indicated to hasten the onset of analgesia and reduce injection pain by bringing an acidic drug solution closer to physiological pH. Its.
The most concrete community description of the practice. Members are clear that no formula transfers between kits because the starting acidity differs, so the method is to add a little, test, and repeat, keeping a.
A short rule of thumb from a 2024 thread that places bicarbonate and acetic acid as opposites: one raises pH, the other lowers it, and the peptide's chemistry decides which, if either, is wanted. It is a community.
This guide positions bicarbonate as the gentler of the two bases used for acidic peptides, the other being ammonium hydroxide. It also states its weaknesses plainly: limited buffering capacity, and sensitivity to.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
2 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
5 rows record what blogs, vendor write-ups or forums describe for Sodium Bicarbonate. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Baking Soda, Sodium hydrogen carbonate, Bicarbonate of soda, NaHCO3, E500(ii), Sodium Bicarbonate Injection 8.4% (1 mEq/mL)
UIIMBOGNXHQVGW-UHFFFAOYSA-M
sodium hydrogen carbonate
3 curated references, each with its journal, year and study model, plus 5 community resources reported but not linked.